Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Validation of a personalized risk prediction model for contralateral breast cancer.

Chowdhury M, Euhus D, Arun B, Umbricht C, Biswas S, Choudhary P.

Breast Cancer Res Treat. 2018 Jul;170(2):415-423. doi: 10.1007/s10549-018-4763-5. Epub 2018 Mar 24.

PMID:
29574637
2.

Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer.

Chowdhury M, Euhus D, O'Donnell M, Onega T, Choudhary PK, Biswas S.

Breast Cancer Res Treat. 2018 Jul;170(1):143-148. doi: 10.1007/s10549-018-4736-8. Epub 2018 Mar 6.

PMID:
29511964
3.

Preliminary Results of a Phase 1 Dose-Escalation Trial for Early-Stage Breast Cancer Using 5-Fraction Stereotactic Body Radiation Therapy for Partial-Breast Irradiation.

Rahimi A, Thomas K, Spangler A, Rao R, Leitch M, Wooldridge R, Rivers A, Seiler S, Albuquerque K, Stevenson S, Goudreau S, Garwood D, Haley B, Euhus D, Heinzerling J, Ding C, Gao A, Ahn C, Timmerman R.

Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):196-205.e2. doi: 10.1016/j.ijrobp.2017.01.020. Epub 2017 Jan 12.

4.

A comparison of trends in operative approach and postoperative outcomes for colorectal cancer surgery.

Addae JK, Gani F, Fang SY, Wick EC, Althumairi AA, Efron JE, Canner JK, Euhus DM, Schneider EB.

J Surg Res. 2017 Feb;208:111-120. doi: 10.1016/j.jss.2016.09.019. Epub 2016 Sep 17.

PMID:
27993198
5.

Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy.

Hunt KK, Euhus DM, Boughey JC, Chagpar AB, Feldman SM, Hansen NM, Kulkarni SA, McCready DR, Mamounas EP, Wilke LG, Van Zee KJ, Morrow M.

Ann Surg Oncol. 2017 Feb;24(2):375-397. doi: 10.1245/s10434-016-5688-z. Epub 2016 Dec 8. Review.

PMID:
27933411
6.

Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.

Antonucci I, Provenzano M, Sorino L, Balsamo M, Aceto GM, Battista P, Euhus D, Cianchetti E, Ballerini P, Natoli C, Palka G, Stuppia L.

J Hum Genet. 2017 Mar;62(3):379-387. doi: 10.1038/jhg.2016.138. Epub 2016 Dec 8.

PMID:
27928164
7.

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

Visvanathan K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, Jeter SC, Sokoll LJ, Garrett-Mayer E, Cope LM, Umbricht CB, Euhus DM, Forero A, Storniolo AM, Nanda R, Lin NU, Carey LA, Ingle JN, Sukumar S, Wolff AC.

J Clin Oncol. 2017 Mar;35(7):751-758. doi: 10.1200/JCO.2015.66.2080. Epub 2016 Nov 21.

8.

Choosing Bilateral Mastectomy.

Euhus DM.

Breast J. 2016 Nov;22(6):605-606. doi: 10.1111/tbj.12654. No abstract available.

PMID:
27870336
9.

A model for individualized risk prediction of contralateral breast cancer.

Chowdhury M, Euhus D, Onega T, Biswas S, Choudhary PK.

Breast Cancer Res Treat. 2017 Jan;161(1):153-160. doi: 10.1007/s10549-016-4039-x. Epub 2016 Nov 4.

10.

Genetic Ancestry using Mitochondrial DNA in patients with Triple-negative breast cancer (GAMiT study).

Rao R, Rivers A, Rahimi A, Wooldridge R, Rao M, Leitch M, Euhus D, Haley BB.

Cancer. 2017 Jan 1;123(1):107-113. doi: 10.1002/cncr.30267. Epub 2016 Sep 1.

11.

Invasive Breast Cancer Preferably and Predominantly Occurs at the Interface Between Fibroglandular and Adipose Tissue.

Zhu W, Harvey S, Macura KJ, Euhus DM, Artemov D.

Clin Breast Cancer. 2017 Feb;17(1):e11-e18. doi: 10.1016/j.clbc.2016.07.009. Epub 2016 Jul 28.

12.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.

13.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750.

14.

Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.

Robinson LS, Hendrix A, Xie XJ, Yan J, Pirzadeh-Miller S, Pritzlaff M, Read P, Pass S, Euhus D, Ross TS.

EBioMedicine. 2015 Oct 21;2(11):1827-33. doi: 10.1016/j.ebiom.2015.10.022. eCollection 2015 Nov.

15.

New Insights into the Surgical Management of Breast Cancer.

Euhus DM.

Semin Radiat Oncol. 2016 Jan;26(1):25-36. doi: 10.1016/j.semradonc.2015.09.007. Epub 2015 Sep 14. Review.

PMID:
26617207
16.

Breast Cancer Screening.

Euhus D, Di Carlo PA, Khouri NF.

Surg Clin North Am. 2015 Oct;95(5):991-1011. doi: 10.1016/j.suc.2015.05.008. Epub 2015 Jul 29. Review.

PMID:
26315519
17.

Contralateral Prophylactic Mastectomy: Challenging Considerations for the Surgeon.

Angelos P, Bedrosian I, Euhus DM, Herrmann VM, Katz SJ, Pusic A.

Ann Surg Oncol. 2015 Oct;22(10):3208-12. doi: 10.1245/s10434-015-4758-y. Epub 2015 Aug 11.

18.
19.

Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.

Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA; Hereditary Breast Cancer Study Group.

Fam Cancer. 2015 Sep;14(3):383-91. doi: 10.1007/s10689-015-9798-8.

20.

Risk-reducing mastectomy for BRCA gene mutation carriers.

Euhus DM.

Ann Surg Oncol. 2015 Sep;22(9):2807-9. doi: 10.1245/s10434-015-4537-9. Epub 2015 Mar 28. No abstract available.

PMID:
25821000
21.

Breast cancer prevention.

Euhus DM, Diaz J.

Breast J. 2015 Jan-Feb;21(1):76-81. doi: 10.1111/tbj.12352. Epub 2014 Nov 20.

PMID:
25413630
22.

Surgery for breast cancer is not obsolete.

Camp M, Euhus D.

Oncology (Williston Park). 2014 Nov;28(11):928-30. No abstract available.

23.

Are axillary lymph nodes still relevant in breast cancer ?

Euhus DM.

Ann Surg Oncol. 2014 Dec;21(13):4051-3. doi: 10.1245/s10434-014-3994-x. Epub 2014 Aug 26. No abstract available.

PMID:
25155394
24.

Genetic testing today.

Euhus D.

Ann Surg Oncol. 2014 Oct;21(10):3209-15. doi: 10.1245/s10434-014-3906-0. Epub 2014 Jul 17.

PMID:
25029991
25.

An internal performance assessment of CancerGene Connect: an electronic tool to streamline, measure and improve the genetic counseling process.

Pritzlaff M, Yorczyk A, Robinson LS, Pirzadeh-Miller S, Lin T, Euhus D, Ross TS.

J Genet Couns. 2014 Dec;23(6):1034-44. doi: 10.1007/s10897-014-9732-5. Epub 2014 Jun 12.

26.

Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index.

Santa-Maria CA, Yan J, Xie XJ, Euhus DM.

Int J Clin Oncol. 2015 Apr;20(2):317-23. doi: 10.1007/s10147-014-0712-4. Epub 2014 Jun 10.

27.

Commentary on the Canadian National Breast Screening study.

Van Zee KJ, Hansen NM, Barrio AV, Connor CS, Danforth DN, Euhus DM, Kulkarni SA, McCready DR, McLaughlin S, Wilke LG.

Ann Surg Oncol. 2014 Dec;21(13):4397-8. doi: 10.1245/s10434-014-3789-0. Epub 2014 May 24.

PMID:
24859935
28.

Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer.

Cockburn A, Yan J, Rahardja D, Euhus D, Peng Y, Fang Y, Rumnong Sarode V.

Hum Pathol. 2014 Feb;45(2):249-58. doi: 10.1016/j.humpath.2013.09.002. Epub 2013 Nov 27.

PMID:
24289969
29.

27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth.

Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, Thompson B, Girard L, Mineo C, Brekken RA, Umetani M, Euhus DM, Xie Y, Shaul PW.

Cell Rep. 2013 Nov 14;5(3):637-45. doi: 10.1016/j.celrep.2013.10.006. Epub 2013 Nov 7.

30.

The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience.

Mauer CB, Pirzadeh-Miller SM, Robinson LD, Euhus DM.

Genet Med. 2014 May;16(5):407-12. doi: 10.1038/gim.2013.160. Epub 2013 Oct 10.

PMID:
24113346
31.

Automation of ROI extraction in hyperspectral breast images.

Kim B, Kehtarnavaz N, LeBoulluec P, Liu H, Peng Y, Euhus D.

Conf Proc IEEE Eng Med Biol Soc. 2013;2013:3658-61. doi: 10.1109/EMBC.2013.6610336.

PMID:
24110523
32.

Identification of breast cancer DNA methylation markers optimized for fine-needle aspiration samples.

Bu D, Lewis CM, Sarode V, Chen M, Ma X, Lazorwitz AM, Rao R, Leitch M, Moldrem A, Andrews V, Gazdar A, Euhus D.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2212-21. doi: 10.1158/1055-9965.EPI-13-0208. Epub 2013 Oct 2.

33.

Axillary node interventions in breast cancer: a systematic review.

Rao R, Euhus D, Mayo HG, Balch C.

JAMA. 2013 Oct 2;310(13):1385-94. doi: 10.1001/jama.2013.277804. Review.

PMID:
24084924
34.

Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.

Bey EA, Reinicke KE, Srougi MC, Varnes M, Anderson VE, Pink JJ, Li LS, Patel M, Cao L, Moore Z, Rommel A, Boatman M, Lewis C, Euhus DM, Bornmann WG, Buchsbaum DJ, Spitz DR, Gao J, Boothman DA.

Mol Cancer Ther. 2013 Oct;12(10):2110-20. doi: 10.1158/1535-7163.MCT-12-0962. Epub 2013 Jul 24.

35.

Genetic predisposition syndromes and their management.

Euhus DM, Robinson L.

Surg Clin North Am. 2013 Apr;93(2):341-62. doi: 10.1016/j.suc.2013.01.005. Epub 2013 Feb 11. Review.

PMID:
23464690
36.

Outcomes of delays in time to treatment in triple negative breast cancer.

Eastman A, Tammaro Y, Moldrem A, Andrews V, Huth J, Euhus D, Leitch M, Rao R.

Ann Surg Oncol. 2013 Jun;20(6):1880-5. doi: 10.1245/s10434-012-2835-z. Epub 2013 Jan 5.

PMID:
23292484
37.

Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer.

Park J, Sarode VR, Euhus D, Kittler R, Scherer PE.

Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):21058-63. doi: 10.1073/pnas.1214400109. Epub 2012 Dec 3.

38.

The clinical consequences of hemizygosity across 2 MB of 10q23 are restricted to Cowden syndrome.

Lewis CM, Bu D, Sarode V, Robinson L, Wilson KS, Viscusi RK, Eng C, Euhus DM.

Breast Cancer Res Treat. 2012 Dec;136(3):911-8. doi: 10.1007/s10549-012-2322-z. Epub 2012 Nov 7.

PMID:
23132533
39.

Auto-fluorescence lifetime and light reflectance spectroscopy for breast cancer diagnosis: potential tools for intraoperative margin detection.

Sharma V, Shivalingaiah S, Peng Y, Euhus D, Gryczynski Z, Liu H.

Biomed Opt Express. 2012 Aug 1;3(8):1825-40. doi: 10.1364/BOE.3.001825. Epub 2012 Jul 9.

40.

A randomised trial of nursing interventions supporting recovery of the postmastectomy patient.

Cho HS, Davis GC, Paek JE, Rao R, Zhao H, Xie XJ, Yousef MG, Fedric T, Euhus DH, Leitch M.

J Clin Nurs. 2013 Apr;22(7-8):919-29. doi: 10.1111/j.1365-2702.2012.04100.x. Epub 2012 Jul 25.

PMID:
22830927
41.

Diabetes, metformin, and breast cancer in postmenopausal women.

Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, Ipp E, Kaklamani VG, Vitolins M, Wallace R, Gunter M, Phillips LS, Strickler H, Margolis K, Euhus DM.

J Clin Oncol. 2012 Aug 10;30(23):2844-52. doi: 10.1200/JCO.2011.39.7505. Epub 2012 Jun 11.

42.

Bootcamp during neoadjuvant chemotherapy for breast cancer: a randomized pilot trial.

Rao R, Cruz V, Peng Y, Harker-Murray A, Haley BB, Zhao H, Xie XJ, Euhus D.

Breast Cancer (Auckl). 2012;6:39-46. doi: 10.4137/BCBCR.S9221. Epub 2012 Feb 1.

43.

Managing the breast in patients who test positive for hereditary breast cancer.

Euhus D.

Ann Surg Oncol. 2012 Jun;19(6):1738-44. doi: 10.1245/s10434-012-2258-x. Epub 2012 Mar 7. Review.

PMID:
22395981
44.

Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.

Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, Gruber SB, Ford JM, Euhus D, Lebensohn A, Telli M, Pochebit SM, Lypas G, Garber JE.

Breast Cancer Res Treat. 2012 Jun;133(3):1125-30. doi: 10.1007/s10549-012-1993-9. Epub 2012 Mar 4.

45.

Influence of surgical technique on mastectomy and reexcision rates in breast-conserving therapy for cancer.

Unzeitig A, Kobbermann A, Xie XJ, Yan J, Euhus D, Peng Y, Sarode V, Moldrem A, Leitch AM, Andrews V, Rao R.

Int J Surg Oncol. 2012;2012:725121. doi: 10.1155/2012/725121. Epub 2012 Jan 16.

46.

Evaluation of a hydrogel based breast biopsy marker (HydroMARK®) as an alternative to wire and radioactive seed localization for non-palpable breast lesions.

Klein RL, Mook JA, Euhus DM, Rao R, Wynn RT, Eastman AB, Leitch AM.

J Surg Oncol. 2012 May;105(6):591-4. doi: 10.1002/jso.22146. Epub 2011 Nov 17.

PMID:
22095610
47.

Atypical endosalpingiosis in axillary sentinel lymph node: a potential source of false-positive diagnosis of metastasis.

Sarode VR, Euhus D, Thompson M, Peng Y.

Breast J. 2011 Nov-Dec;17(6):672-3. doi: 10.1111/j.1524-4741.2011.01164.x. Epub 2011 Sep 23. No abstract available.

PMID:
21951608
48.

Axillary lymph node dissection for breast cancer utilizing Harmonic Focus®.

Ostapoff KT, Euhus D, Xie XJ, Rao M, Moldrem A, Rao R.

World J Surg Oncol. 2011 Aug 15;9:90. doi: 10.1186/1477-7819-9-90.

49.

Volume of excision and cosmesis with routine cavity shave margins technique.

Mook J, Klein R, Kobbermann A, Unzeitig A, Euhus D, Peng Y, Sarode V, Moldrem A, Leitch AM, Andrews V, Teotia S, Rao R.

Ann Surg Oncol. 2012 Mar;19(3):886-91. doi: 10.1245/s10434-011-1982-y. Epub 2011 Aug 12.

PMID:
21837529
50.

Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.

Euhus D, Bu D, Xie XJ, Sarode V, Ashfaq R, Hunt K, Xia W, O'Shaughnessy J, Grant M, Arun B, Dooley W, Miller A, Flockhart D, Lewis C.

Cancer Prev Res (Phila). 2011 Nov;4(11):1852-62. doi: 10.1158/1940-6207.CAPR-11-0186. Epub 2011 Jul 21.

Supplemental Content

Support Center